Scientists guilty of 'hyping' benefits of gene research
By The Independent,
The Independent (UK)
| 09. 05. 2005
The leading fertility scientist Lord Winston has hit out at senior scientists, including two Nobel laureates, for making exaggerated claims about the supposed benefits of scientific research, warning they could trigger a public backlash.
Speaking on the eve of his presidential address to the annual meeting of the British Association for the Advancement of Science at Trinity College, Dublin, the former head of fertility medicine at the Hammersmith Hospital in London also criticised the "hype" over stem cells. He said stem cells are unlikely to be of much use for many years.
Lord Winston called on his colleagues to use more moderate language when describing scientific breakthroughs, singling out in his speech senior scientists and naming two Nobel laureates for making dangerously arrogant remarks.
"James Watson's assertion about the value of tampering with the human germ-line are a pretty good example," he said. Professor Watson, who won a Nobel prize for discovering the DNA double helix with Francis Crick, has extolled the possibility of altering the genes of germ-line sperm or egg cells to eradicate inherited diseases.
Lord Winston also...
Related Articles
By Jenny Kleeman, The Guardian | 05.30.2026
On a Friday evening in late April, Cathy Tie, the Canadian serial entrepreneur and self-styled “Biotech Barbie”, is centre stage at New York City’s famous Carnegie Hall, performing Saint-Saens’ Piano Concerto No 2 on a gleaming Steinway grand piano, accompanied...
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Rebecca Roberts, The Scientist | 05.19.2026
Scientists have had prenatal gene therapy in their sights for decades; by treating the fetus in utero, they can potentially prevent the long-term damage caused by severe, early-onset genetic disorders. Despite its success in preclinical studies, the method has...
By Moe Alsumidaie, The Clinical Trial Vanguard | 05.26.2026
Picture the moment a gene therapy trial’s safety monitor pulls up a patient record — years after the last dose, long after the trial team has dissolved and the CRO contract has closed — and finds a tumor. The vector...
